Clinical trials: Fluorescence
Ophthalmic, Healthy Eyes
ClearPath DS-120 Clinical Study Protocol
The goal of this study is to measure lens fluorescence in normal subjects at various chronological ages that could serves as a guide to clinicians in determining changes in eye health.
- Trial name
- NCT01425346
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Freedom Meditech
Thyroid Disease, Thyroid Surgery
Intraoperative Parathyroid Gland (PTG) Identification Using a Hand-Held Imager (HHI)
It is often challenging to tell apart the parathyroid glands from the surrounding area such as lymph nodes, fat and thyroid tissue.
- Conditions
- Thyroid Disease, Thyroid Surgery, Parathyroid Gland
- Trial name
- NCT06939946
- Testing
- Parathyroid auto-fluorescence imaging, Indocyanine green
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- OPTOSURGICAL, LLC
Brain Neoplasm
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
This study is planned to detect a dose-efficacy relationship between the chosen dose levels of MC506/1 and the extent and quality of fluorescence in the tumour core in patients with newly diagnosed malignant glioma.
- Trial name
- NCT02755142
- Testing
- Gliolan
- Volunteers
- 21 people
- Sponsor
- medac GmbH
Low Grade Glioma of Brain, Glioblastoma
Feasibility of the LUM Imaging System for Detection of Cancer to the Brain
The overall objective of this study is to assess the safety and efficacy of the LUM Imaging System in imaging primary and metastatic cancer in the brain.
- Conditions
- Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
- Trial name
- NCT03717142
- Testing
- LUM Imaging System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Lumicell, Inc.
Breast Cancer
Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry
This is a minimal risk post-market registry study conducted at participating clinical institutions that are utilizing LumiSystem consistent with the U.S.
- Trial name
- IMPACT (NCT07616856)
- Where
- 2 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Lumicell, Inc.
Prostate Cancer
IS-002 Phase 2 Prostate Cancer Study
Phase 2 randomized controlled multi-center study of IS-002, in conjunction with near-infrared (NIR) fluorescence imaging, for identification of prostate cancer during robotic-assisted radical prostatectomy (RARP) with (extended)…
- Trial name
- NCT05946603
- Testing
- Administration of IS-002, Firefly fluorescent imaging, robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Intuitive Surgical
Wound
Evaluation of MolecuLight i:X as an Adjunctive Fluorescence Imaging Tool to Clinical Signs and Symptoms for the Identification of Bacteria-containing Wounds
This is a non-randomized evaluation for which 160 adult patients will be imaged at outpatient wound care clinics who present with a wound of unknown infection diagnostic status and are receiving standard treatment.
- Trial name
- NCT03540004
- Testing
- MolecuLight i:X Imaging Device
- Where
- 14 sites in United States
- Volunteers
- 367 people
- Sponsor
- MolecuLight Inc.
Glomerular Filtration Rate, Acute Kidney Injury
Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers
The purpose of this early feasibility study was to investigate the pharmacokinetics of MP-3180 administered in rising doses and to evaluate the use of the Optical Renal Function Monitor (ORFM), an investigational noninvasive…
- Trial name
- ORFM-1B (NCT02098187)
- Testing
- Below target dose MP-3180, At target dose MP-3180, 2 times above target dose MP-3180
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging
- Trial name
- LUMA-PSMA (NCT06906471)
- Testing
- AS1986NS
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Antelope Surgical Solutions, Inc
Prostate Cancer, Neoplasm, Residual
Feasibility of the LUM Imaging System for Detection of Prostate Cancer
The primary objective of this feasibility study is to determine if administration of LUM015 will result in positive fluorescence of tumor tissue from ex vivo specimen imaging with the LUM Imaging device from patients undergoing…
- Trial name
- NCT03441464
- Testing
- LUM Imaging System
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Lumicell, Inc.
Intraoperative Ureter Visualization, Abdominolpelvic Surgery
A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery
The ureter was the tube that carries urine from the kidneys to the bladder. It was difficult for surgeons to see the ureter during abdominal surgery. This could lead to injuring the ureter which, although rare, could be serious.
- Trial name
- NCT05754333
- Testing
- pudexacianinium chloride
- Where
- 6 sites in United States
- Volunteers
- 107 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cancer in the Lung, Ovarian Cancer
CYTALUX Dose Extension Study
The goal of this clinical trial is to learn whether giving Cytalux™ (pafolacianine) injection several days before surgery works as well as giving it closer to the time of surgery for helping surgeons see lesions during an…
- Trial name
- NCT07469202
- Testing
- CYTALUX (pafolacianine) injection
- Volunteers
- 106 people
- Sponsor
- On Target Laboratories, LLC
Rectal Cancer, Rectosigmoid Cancer
A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection
This is a randomized, controlled, parallel, multicenter study to determine the difference in post-operative anastomotic leak rate in low anterior resection procedures where colon and rectal tissue perfusion is evaluated using…
- Trial name
- PILLAR III (NCT02205307)
- Testing
- PINPOINT, SPY Elite
- Where
- 24 sites in United States
- Volunteers
- 347 people
- Sponsor
- Novadaq Technologies ULC, now a part of Stryker
Neoplasms, Breast
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the…
- Trial name
- NCT00347919
- Testing
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg
- Where
- 84 sites in United States, Canada and 14 more
- Volunteers
- 189 people
- Sponsor
- GlaxoSmithKline
Hepatic Failure, Liver Failure
Cardiox Liver Function Test Pivotal Trial
Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum…
- Trial name
- LFT-0002 (NCT02552901)
- Testing
- 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cardiox Corporation
Cervical Neoplasia
Spectroscopic Evaluation of Cervical Neoplasia
The overall objective of this study is to evaluate whether fluorescence and reflectance spectroscopy can improve the ability to detect the presence of premalignant lesions on the cervix.
- Trial name
- NCT00766701
- Testing
- Procedure: Spectroscopy and Digital Imaging
- Where
- 7 sites in United States
- Volunteers
- 1,599 people
- Sponsor
- Guided Therapeutics
Psoriasis Vulgaris
The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic Patients
This is a two-center study aimed to assess the efficacy of Dead Sea Minerals in alleviating symptoms of Psoriasis Vulgaris, in 50 patients undergoing phototherapy.
- Trial name
- NCT01651559
- Where
- 2 sites in Israel
- Volunteers
- 50 people
- Sponsor
- Ahava Dead Sea Laboratories
Geographic Atrophy
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic…
- Trial name
- NCT02515942
- Testing
- CLG561, LFG316
- Volunteers
- 114 people
- Sponsor
- Alcon Research
Wounds
Positive Predictive Value of the MolecuLight i:X Imaging Device to Predict the Presence of Bacteria in Chronic Wounds
This is a non-randomized evaluation for which 50 patients will be imaged at the Southwest Regional Wound Care Center, Lubbock, Texas, who present with a chronic wound and are receiving standard treatment.
- Trial name
- NCT02682069
- Testing
- MolecuLight i:X Imaging Device
- Volunteers
- 30 people
- Sponsor
- MolecuLight Inc.
Non-Healing Ulcer of Skin, Autofluorescence Imaging
Retrospective Database Review at LTC and SNFs
The goal of this observational study is to compare the differences in wound outcomes when the MolecuLight imaging procedure is used in combination with standard of care wound assessment in long term care and skilled nursing…
- Trial name
- NCT06068972
- Testing
- MolecuLight
- Where
- United States
- Volunteers
- 193 people
- Sponsor
- Wound Care Plus, LLC